Analytes Retention time (TR) (min) Capacity factor (K’) Theoretical plates (N) Tailing factor (T) Resolution (R) Separation factor (α) pH 2.7  ±  0.05 Phase-1 Lef 2.9 ± 0.024 0.54 ± 0.013 7182 ± 0.58.2 1.26 ± 0.09 1.26 ± 0.14 2.68 ± 0.06 Flur 3.37 ± 0.21 0.75 ± 0.101 7606 ± 0.37.9 1.18 ± 0.093 1.18 ± 0.07 1.37 ± 0.13 Ibu 3.8 ± 0.18 0.96 ± 0.021 9769 ± 53.1 1.17 ± 0.17 1.17 ± 0.10 1.29 ± 0.21 Phase-2 Lef 2.9 ± 0.08 0.41 ± 0.051 7229 ± 53 1.21 ± 0.11 1.21 ± 0.15 3.9 ± 0.15 Diclo 3.6 ± 0.23 0.73 ± 0.019 7735 ± 78 1.15 ± 0.07 1.15 ± 0.084 1.78 ± 0.05 Mef 4.9 ± 0.15 1.34 ± 0.09 8629 ± 23 1.14 ± 0.13 1.14 ± 0.17 1.82 ± 0.29 Flow rate 1.5 ±  0.2 Phase-1 Lef 2.91 ± 0.13 0.54 ± 0.08 7181 ± 67 1.25 ± 0.13 1.262 ± 0.05 2.68 ± 0.21 Flur 3.367 ± 0.16 0.75 ± 0.051 7619 ± 25 1.182 ± 0.07 1.19 ± 0.12 1.37 ± 0.07 Ibu 3.81 ± 0.25 0.96 ± 0.13 9771 ± 89 1.20 ± 0.15 1.16 ± 0.11 1.29 ± 0.061 Phase-2 Lef 2.9 ± 0.13 0.41 ± 0.087 7230 ± 33 1.21 ± 0.16 1.21 ± 0.18 3.9 ± 0.22 Diclo 3.6 ± 0.098 0.73 ± 0.12 7743 ± 27 1.15 ± 0.59 1.15 ± 0.12 1.78 ± 0.09 Mef 4.9 ± 0.14 1.34 ± 0.21 8631 ± 76 1.14 ± 0.2 1.14 ± 0.19 1.82 ± 0.13 Methanol percentage 80 ±  2% Phase-1 Lef 2.89 ± 0.21 0.539 ± 0.07 7183 ± 83 1.26 ± 0.06 1.21 ± 0.051 2.66 ± 0.08 Flur 3.36 ± 0.31 0.752 ± 0.052 7616 ± 34 1.18 ± 0.09 1.15 ± 0.21 1.37 ± 0.31 Ibu 3.81 ± 0.09 0.95 ± 0.12 9760 ± 67 1.17 ± 0.14 1.14 ± 0.17 1.30 ± 0.16 Phase-2 Lef 2.91 ± 0.19 0.41 ± 0.05 7243 ± 49 1.21 ± 0.11 1.20 ± 0.08 3.9 ± 0.07 Diclo 3.56 ± 0.22 0.73 ± 0.061 7727 ± 33 1.15 ± 0.097 1.14 ± 0.019 1.78 ± 0.25 Mef 4.89 ± 0.071 1.34 ± 0.074 8632 ± 92 1.14 ± 0.13 1.21 ± 0.13 1.82 ± 0.31 Lef=leflunomide, Flur=flurbiprofen, Ibu=ibuprofen, Mef=mefanamic acid, Diclo=diclofenac sodium. All data presented in mean ± standard deviation (n=6)

Table 1: System suitability and ruggedness of the developed method.